Rhythm Pharmaceuticals
setmelanotide
acquired hypothalamic obesity
Resolved
109days ago
FDA decision · Mar 20, 2026
What's at stake
The FDA's approval decision on setmelanotide for acquired hypothalamic obesity is due Mar 20, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“the FDA’s assigned PDUFA goal date is March 20, 2026”